Combined detection of serum UL16-binding protein 2 and macrophage inhibitory cytokine-1 improves early diagnosis and prognostic prediction of pancreatic cancer

被引:19
|
作者
Zhou, Yu-Fen [1 ]
Xu, Ling-Xiao [1 ]
Huang, Li-Ya [2 ]
Guo, Fang [1 ]
Zhang, Fan [1 ]
He, Xiang-Yi [1 ]
Yuan, Yao-Zong [1 ]
Yao, Wei-Yan [1 ]
机构
[1] Shanghai Jiao Tong Univ, Dept Gastroenterol, Ruijin Hosp, Sch Med, Shanghai 200025, Peoples R China
[2] Ningxia Med Univ, Gen Hosp, Dept Gastroenterol, Ningxia, Peoples R China
关键词
macrophage inhibitory cytokine-1; serum biomarker; pancreatic cancer; UL16-binding protein 2; BETA; CA19-9; CELLS; METASTASIS; MARKERS; GROWTH; MEMBER; TOOL;
D O I
10.3892/ol.2014.2429
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic cancer (PC) is the fourth leading cause of cancer-related mortality in the United States. There is no effective serum biomarker for the early diagnosis of PC at present. Although serum UL16-binding protein 2 (ULBP2) and macrophage inhibitory cytokine-1 (MIC-1) levels are reported to be elevated in PC patients, the diagnostic and prognostic value of ULBP2 and MIC-1 alone or in combination remains unknown. The aim of the present case-control study was to compare the diagnostic value of ULBP2, MIC-1 and carbohydrate antigen 19-9 (CA19-9) in 359 serum samples, consisting of 152 cases of PC, 20 cases of pre-pancreatic cancer, 91 cases of chronic pancreatitis (CP) and 96 normal controls (NC). All patients were followed up for a median of 2 years. It was found that the serum levels of ULBP2, MIC-1 and CA19-9 were significantly higher in the PC patients compared with those in the NC group. In distinguishing PC from the CP, the highest sensitivity and specificity were ULBP2 (0.878) and CA19-9 (0.816), respectively. The area under the receiver operating characteristic curve of ULBP2 was 0.923, which was the highest of the three biomarkers. MIC-1 was the optimal choice for the diagnosis of early-stage PC (area under the curve, 0.831). Overall, MIC-1 in combination with ULBP2 improved the diagnostic accuracy in differentiating PC from CP and NC. In addition, a higher level of MIC-1 was correlated with a poorer prognosis, as calculated by the Kaplan-Meier test (P=0.039). Patients with serum MIC-1 levels of >= 1,932 ng/ml had a median survival time of 15.62 +/- 2.44 months (mean +/- standard deviation) vs. 18.66 +/- 2.43 months in patients with a lower level of MIC-1. Overall, combined detection of serum MIC-1 and ULBP2 improved the diagnostic accuracy in differentiating PC from CP and NC, and serum MIC-1 level alone was a predictor of survival in the patients with PC.
引用
收藏
页码:2096 / 2102
页数:7
相关论文
共 8 条
  • [1] UL16-binding protein 1 is a significant prognostic and diagnostic marker for breast cancer
    Zhang, Xiaowei
    Dai, Shuhong
    Li, Liang
    Wang, Pengyun
    Dong, Mingxin
    ONCOLOGY LETTERS, 2025, 29 (01)
  • [2] Diagnostic and prognostic impact of serum-soluble UL16-binding protein 2 in lung cancer patients
    Yamaguchi, Kosuke
    Chikumi, Hiroki
    Shimizu, Asuka
    Takata, Miyako
    Kinoshita, Naoki
    Hashimoto, Kiyoshi
    Nakamoto, Masaki
    Matsunaga, Shinji
    Kurai, Jun
    Miyake, Naomi
    Matsumoto, Shingo
    Watanabe, Masanari
    Yamasaki, Akira
    Igishi, Tadashi
    Burioka, Naoto
    Shimizu, Eiji
    CANCER SCIENCE, 2012, 103 (08) : 1405 - 1413
  • [3] Soluble UL16-binding protein 2 is associated with a poor prognosis in pancreatic cancer patients
    Kegasawa, Tadashi
    Tatsumi, Tomohide
    Yoshioka, Teppei
    Suda, Takahiro
    Ikezawa, Kenji
    Nakabori, Tasuku
    Yamada, Ryoko
    Kodama, Takahiro
    Shigekawa, Minoru
    Hikita, Hayato
    Sakamori, Ryotaro
    Takehara, Tetsuo
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2019, 517 (01) : 84 - 88
  • [4] Serum macrophage inhibitory cytokine-1 serves as a novel diagnostic biomarker of early-stage colorectal cancer
    Dai, Chunyang
    Zhang, Xiaolei
    Ma, Yanling
    Chen, Zhaowu
    Chen, Shaohua
    Zhang, Yang
    Li, Ming
    BIOMARKERS, 2021, 26 (07) : 598 - 605
  • [5] Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis
    Brown, DA
    Stephan, C
    Ward, RL
    Law, M
    Hunter, M
    Bauskin, AR
    Amin, J
    Jung, K
    Diamandis, EP
    Hampton, GM
    Russell, PJ
    Giles, GG
    Breit, SN
    CLINICAL CANCER RESEARCH, 2006, 12 (01) : 89 - 96
  • [6] Serum levels of macrophage inhibitory cytokine-1 (MIC1) and matrix metallopeptidase-7 (MMP7) as diagnostic and prognostic markers in gastric cancer (GC) patients (pts)
    Valladares-Ayerbes, Manuel
    Tarrio, Nuria
    Blanco-Calvo, Moises
    Haz-Conde, Mar
    Santamarina Cainzos, Isabel
    Medina Villaamil, Vanessa
    Rodriguez-Rigueiro, Teresa
    Figueroa, Angelica
    Reboredo, Margarita
    Anton-Aparicio, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Macrophage inhibitory cytokine-1 versus carbohydrate antigen 19-9 as a biomarker for diagnosis of pancreatic cancer: A PRISMA-compliant meta-analysis of diagnostic accuracy studies
    Yang, Ying
    Yan, Shirong
    Tian, Hui
    Bao, Yixi
    MEDICINE, 2018, 97 (09)
  • [8] RETRACTED: Diagnostic Performance of Serum Macrophage Inhibitory Cytokine-1 in Pancreatic Cancer: A Meta-Analysis and Meta-Regression Analysis (Retracted article. See vol. 34, pg. 742, 2015)
    Chen, Yan-Zhi
    Liu, Dan
    Zhao, Yu-Xia
    Wang, He-Tong
    Gao, Ya
    Chen, Ying
    DNA AND CELL BIOLOGY, 2014, 33 (06) : 370 - 377